Advertisement
Advertisement
U.S. Markets open in 2 hrs 8 mins
Advertisement
Advertisement
Advertisement
Advertisement

Vir Biotechnology, Inc. (VIR)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
23.09+0.81 (+3.64%)
At close: 04:00PM EDT
23.08 -0.01 (-0.04%)
After hours: 07:58PM EDT
Advertisement
Full screen
Loading interactive chart...
  • Benzinga

    HC Wainwright Says This Stock Is Well Capitalized For Value Realization Of Pipeline, Despite COVID-19 Uncertainty

    Given the uncertainty, HC Wainwright moderated its COVID-19 franchise estimates, the primary driver of estimate reductions, and price target reduction to $125 (from $200) on Vir Biotechnology Inc (NASDAQ: VIR). The analyst maintained a Buy rating on VIR shares. The analyst continues to view Vir's platform, validated with successful antiviral therapies against Ebola and COVID-19, and pipeline, which includes compounds in development for chronic hepatitis B virus (CHB), human immunodeficiency viru

  • Zacks

    Vir Biotechnology, Inc. (VIR) Q1 Earnings and Revenues Beat Estimates

    Vir Biotechnology, Inc. (VIR) delivered earnings and revenue surprises of 19.94% and 80.87%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

  • GlobeNewswire

    Vir Biotechnology Provides Corporate Update and Reports First Quarter 2022 Financial Results

    – $1.2 billion of sotrovimab collaboration revenue recognized in the first quarter – – More than $2.5 billion in cash, cash equivalents, investments and collaboration receivables at the end of the first quarter – – Encouraging initial data from MARCH trial evaluating hepatitis B functional cure shared in April – – Multiple value drivers in COVID-19, hepatitis B, hepatitis D, HIV and influenza expected in 2022 – SAN FRANCISCO, May 05, 2022 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (Nasdaq: VIR)

Advertisement
Advertisement